| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
The compound functions as a modulator of A1 and A3 adenosine receptors. Its antiviral activity against EV71 is mediated through the inhibition of the interaction between EV71 and its cellular uncoating factor cyclophilin A.
|
|---|---|
| ln Vitro |
The interaction between EV71 and its cellular uncoating factor, cyclophilin A, is inhibited by Bright Black BN (E151) [1]. At a dosage of 300 μM, bright black BN (E151) suppressed infection with EV71-GFP, as seen by the decrease in GFP signal. With an IC50 value of 10.1 μM, brilliant black BN (E151) suppresses EV71 -GFP in infected RD cells in a dose-dependent manner[1]. All 28 of the tested EV71, CVA16, and CVA6 strains are inhibited by Bright Black BN (E151). The 50% cytotoxic dosage of dye E151 was 1870 μM in rhabdomyosarcoma cells, although its 50% inhibitory value on different EV71 strains ranged from 2.39 μM to 28.12 μM [1].
Brilliant Black BN reduces the infectivity of enterovirus 71 (EV71) in rhabdomyosarcoma cells with an IC50 of 10.1 µM via inhibition of viral entry. These findings highlight its potential as an antiviral agent beyond its traditional use as a food colorant. |
| ln Vivo |
Brilliant Black BN (E151) (ip; 200 mg/kg; 14 days) exhibited modest illness with clinical scores < 3 in comparison to the PBS group, and recovered thereafter. Throughout the trial, every mouse treated with E151 270 received complete protection [1].
In vivo antiviral efficacy of Brilliant Black BN has been suggested by its mechanism of action against EV71. However, detailed in vivo studies are not extensively reported in the available literature. The compound is primarily known for its use as a food additive. |
| Enzyme Assay |
Antiviral activity assays are performed using rhabdomyosarcoma cells infected with EV71. Cells are treated with varying concentrations of Brilliant Black BN, and viral infectivity is measured. The IC50 of 10.1 µM is determined from dose-response curves.
|
| Cell Assay |
Cell-based antiviral assays are conducted using rhabdomyosarcoma cells to evaluate the compound's ability to inhibit EV71 infection. Cells are treated with Brilliant Black BN at various concentrations, and the reduction in viral infectivity is assessed. The compound inhibits viral entry by blocking the interaction with cyclophilin A.
|
| Animal Protocol |
Animal/Disease Models: 14-day-old AG129 mice infected with EV71 [1]
Doses: 200 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: It has a protective effect on EV71 in AG129 mice challenged with dye E151. In vivo studies for Brilliant Black BN are not extensively reported in the available literature, as the compound is primarily used as a food colorant and research reagent. Its potential as an antiviral agent would require further in vivo validation. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Brilliant Black BN are not extensively reported in the available literature. As a food colorant, the compound's absorption and metabolism have been evaluated for safety assessment. Detailed PK data would require further investigation from toxicological studies.
|
| Toxicity/Toxicokinetics |
Brilliant Black BN has been approved for use as a food colorant (E151) in various regions. It is considered safe for consumption at permitted levels. Its use as a research reagent for antiviral studies is an emerging application. Comprehensive toxicity data are available from food safety assessments.
|
| References |
|
| Additional Infomation |
Brilliant Black BN is primarily known as a synthetic azo dye and food colorant (E151). It has recently been identified as a promising antiviral agent against EV71 infection by inhibiting viral entry. The compound is also used in diagnostic assay manufacturing and hematology applications.
|
| Molecular Formula |
C₂₈H₁₇N₅NA₄O₁₄S₄
|
|---|---|
| Molecular Weight |
867.68
|
| Exact Mass |
866.924
|
| CAS # |
2519-30-4
|
| PubChem CID |
17293
|
| Appearance |
Brown to black solid powder
|
| LogP |
8.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
55
|
| Complexity |
1730
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GMMAPXRGRVJYJY-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/C28H21N5O14S4.4Na/c1-14(34)29-23-10-11-24(50(42,43)44)20-13-25(51(45,46)47)27(28(35)26(20)23)33-32-22-9-8-21(18-7-6-17(12-19(18)22)49(39,40)41)31-30-15-2-4-16(5-3-15)48(36,37)38;;;;/h2-13,35H,1H3,(H,29,34)(H,36,37,38)(H,39,40,41)(H,42,43,44)(H,45,46,47);;;;/q;4*+1/p-4
|
| Chemical Name |
tetrasodium;4-acetamido-5-hydroxy-6-[[7-sulfonato-4-[(4-sulfonatophenyl)diazenyl]naphthalen-1-yl]diazenyl]naphthalene-1,7-disulfonate
|
| Synonyms |
Brilliant Black BN; Brilliant Black BN
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~144.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1525 mL | 5.7625 mL | 11.5250 mL | |
| 5 mM | 0.2305 mL | 1.1525 mL | 2.3050 mL | |
| 10 mM | 0.1152 mL | 0.5762 mL | 1.1525 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
